ClinAssess

NCT00508664

Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)

NCT00925821

Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

NCT00932724

CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer

NCT01081431

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

NCT01328171

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

NCT01377025

A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

NCT01418742

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment

NCT01388621

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

NCT01509560

PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

NCT01639261

A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT

NCT01991873

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

NCT02125136

Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

NCT02047513

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

NCT02166658

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)

NCT02564146

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

NCT04034173

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

NCT03620903

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

NCT05217069

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC